Evaluating the efficacy and safety of Danning Pian in the short-term treatment of patients with non-

来源 :Hepatobiliary & Pancreatic Diseases International | 被引量 : 0次 | 上传用户:wu000mengya
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
BACKGROUND: Currently, the managment of non-alco-holic fatty liver disease (NAFLD) is less than certain. Somecholeretic might be of potential benefit and deserve furtherevaluation. This multicenter clinical trial was designed toevaluate the efficacy and safety of Chinese herbal medicineDanning Pian ( composed of rhubarb, grant knotweed,dried green orange peel and dried old orange peel) in theshort-term treatment of patients with NAFLD.METHODS: The efficacy and safety of Danning Pian in theshort-term treatment of NAFLD were investigated in 232patients by a multicenter clinical trial during the period ofJuly 1999 to February 2000. The patients consisting of 189males and 43 females with an average age of 46.1 ±8.7 yearswere given 3-5 tablets of Danning Pian orally thrice dailyfor 3 months in addition to the other comprehensive thera-py. The effects of Danning Pian on NAFLD were evaluatedby the improvement of clinical symptoms, blood lipids,hepatic enzymes and liver ultrasonographic features. Thedrug safety was monitored by physical examinations, vitalsigns, and laboratory tests in addition to the assessment ofthe adverse events.RESULTS: All the enrolled patients completed the study ex-cept one whose serum ALT level was moderately increasedduring the therapy with Danning Pian. The effective rate ofDanning Pian for the improvement of clinical symptoms,serum ALT levels, blood lipid and fatty liver was 85.8%,78.2%, 39.6% and 34.0% respectively after the therapy for3 months. However, the reduction of excessive bodyweight and waistline did not reach the significant level onthe whole after the therapy. The general mild adverseevents included diarrhea, skin rash and mild to moderateelevation of serum ALT level. The incidence of adverse re-action was 15.1%.CONCLUSION: The data of this trial indicate that DanningPian is effective and safe, generally well-tolerated withoutsevere adverse events, in the treatment of patients withNAFLD over a 3-month period. BACKGROUND: Currently, the managment of non-alco-holic fatty liver disease (NAFLD) is less than certain. Somecholeretic might be of potential benefit and deserve furtherevaluation. This multicenter clinical trial was designed to evaluate the efficacy and safety of Chinese herbal medicine Danning Pian ( composed of rhubarb, grant knotweed, dried green orange peel and dried old orange peel) in the short-term treatment of patients with NAFLD. METHHODS: The efficacy and safety of Danning Pian in the short-term treatment of NAFLD were investigated in 232 patients by a multicenter clinical trial during the period of June 1999 to February 2000. The patient consisting of 189 males and 43 females with an average age of 46.1 ± 8.7 yearswere given 3-5 tablets of Danning Pian orally thrice daily for 3 months in addition to the other comprehensive thera-py The effects of Danning Pian on NAFLD were evaluated by the improvement of clinical symptoms, blood lipids, hepatic enzymes and liver ultrasonographic featu res. Thedrug safety was monitored by physical examinations, vitalsigns, and laboratory tests in addition to the assessment of the adverse events .RESULTS: All the enrolled patients completed the study ex-cept one whose serum ALT level was moderately increased dormant the therapy with Danning Pian. The effective rate of Daning Pian for the improvement of clinical symptoms, serum ALT levels, blood lipid and fatty liver was 85.8%, 78.2%, 39.6% and 34.0% respectively after the therapy for 3 months. However, the reduction of excessive bodyweight and waistline did not reach the significant level on the whole after the therapy. The general mild adverseevents included diarrhea, skin rash and mild to moderate elevation of serum ALT level. The incidence of adverse re-action was 15.1% .CONCLUSION: The data of this trial indicate that DanningPian is effective and safe, generally well-tolerated without serious adverse events, in the treatment of patients with NAFLD over a 3-month period.
其他文献
鸡西矿业集团公司张辰煤矿西三采区3
11月4日,工业和信息化部副部长奚国华行到黑龙江省通信管理局视察,听取了黑龙江省通信管理局局长胡立志的工作汇报,察看了黑龙江省通信网络资源管理系统。奚国华副部长充分肯
患者男,32岁,干部,因"反复腹泻、腹胀3年"入院,3年来,患者反复查大便常规,大便培养均无异常,肝功能正常,乙状结肠镜检查无异常发现,平素元烟酒嗜好,按"慢性结肠炎"服中西药治
新浪动作频频!2010年1月28日,新浪与中国奥委会共同举办发布会,宣布新浪正式成为中国奥委会合作伙伴、中国奥委会互联网服务合作伙伴、中国体育代表团合作伙伴、中国体育代表
椎基底动脉供血不足(vertebrobasilar insufficiency,VBI)是椎基底动脉系统循环不全引起脑干、小脑、大脑半球后部等灌注区功能障碍所致的症状。其主要临床表现为眩晕,大多以
<正> 陈共,1927年生,辽宁省盖县人。现任中国人民大学财政金融系教授、博士生导师,并兼任中国财政学会常务理事、中国税务学会常务理事、中国企业财务研究会副总干事、中国经济杠杆研究会副总干事、北京经济学会总会理事、《财贸经济》和《财政研究》两杂志的编委等职。
目的 观察拉米夫定联合肝立克治疗活动性肝炎肝硬化的疗效.方法选择105例活动性乙型肝炎肝硬化病例随机分为Ⅰ组(拉米夫定+肝立克)40例,Ⅱ组(肝立克)30例,Ⅲ组35例(拉米夫定),疗程半年,治疗前和治疗后每月检测HA、LN、Pc-Ⅲ、ALT、AST、HBV-DNA并进行比较.结果治疗后Ⅰ组各项指标恢复正常的时间明显短于Ⅱ组和Ⅲ组,差异有显著意义(P<0.01);HBV-DNA阴转率Ⅰ组为67.5
在2008年百度很多关键管理人员出走后,新一轮的大震荡又开始了。2010年1月18日下午,百度公司宣布,CTO李一男正式离职,仅10天前,其首席运营官叶朋辞职,而产品副总裁俞军也在20
目的探讨预测脑梗死早期病情进展的危险因素。方法将70例进展型脑梗死与同期住院随机抽取的106例非进展型脑梗死的临床资料进行对照分析。结果进展组患者平均年龄为62.44±9.
为满足紧急作战需求,英国陆军计划进一步升级SA80A2(L85A2)突击步枪。此前,在2000年HK公司已经对SA80步枪进行了一次升级改造,并为其配装了闭锁装置和枪机、复进簧、击针、拉